Prevent efficacy pool: this contract supports the prevent cancer preclinical drug development program, which provides a structured approach to drug and vaccine development, from discovery to the…

Ended Awarded Last action

Contract number
75N91019D00019
Awardee
Awarding agency
Task orders
3 $2,679,142 obligated

Award facts

Combined order value
$2,679,142 Current and potential, with all options
Last date to order 100% complete
IDV ceiling 5% used
$49,995,000.00
Award type
Multiple award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 9 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)
Legislative mandates

Award details come from SAM.gov/FPDS.

Description

As the agency reported it.

Prevent efficacy pool: this contract supports the prevent cancer preclinical drug development program, which provides a structured approach to drug and vaccine development, from discovery to the clinic. This contract is part of a multiple-award indefinite delivery indefinite quantity (IDIQ) pool to procure services related to preclinical efficacy and intermediate endpoint biomarkers, which is also referred to as the "efficacy pool."

Task orders

Task order Ordering agency Obligated Awarded
Further development of colovac, a multi-antigen multi-peptide vaccine, for colon cancer prevention 75N91019F00131 National Cancer Institute (NIH) $1,044,896
Task order: evaluation of two different classes of compounds (STAT3 inhibitors and serms) for the prevention of urinary… 75N91019F00130 National Cancer Institute (NIH) $135,660
Task order: colorectal cancer prevention by a novel EPA analogue TP-252 and naproxen in FAP and lynch syndrome models 75N91019F00132 National Cancer Institute (NIH) $1,498,586

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Supplemental Agreement for work within scope P00002 · Prevent cancer preclinical drug development program: preclinical efficacy and intermediate endpoint biomarkers. Period of performance: 01/25/2019 - 01/24/2024 $0
Other Administrative Action P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N91019D00019?

75N91019D00019 was awarded to University Of Alabama At Birmingham by National Cancer Institute (National Institutes of Health) on January 23, 2019.

How much is contract 75N91019D00019 worth?

Orders under 75N91019D00019 have obligated $2,679,142. 75N91019D00019's own ceiling is $49,995,000.

How many orders have been placed under contract 75N91019D00019?

3 orders have been placed under 75N91019D00019, the latest on September 15, 2019.

Who can order from contract 75N91019D00019?

75N91019D00019 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract 75N91019D00019 part of a contract vehicle?

Yes. 75N91019D00019 is part of PREVENT Preclinical Drug Development Program (PREVENT).

Was contract 75N91019D00019 competed?

The extent of competition for 75N91019D00019 was full and open competition. The government received 9 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login